Contact us

About HanchorBio

About US
HanchorBio was founded at the end of 2020, focusing on the development of innovative drugs for cancer and autoimmune diseases. Since its establishment, it has pioneered a precise oncology treatment model through its proprietary FBDB™ technology platform. With unique drug design and clinical strategies, HanchorBio is driving cancer therapy into a new era of greater efficacy and safety.

Award-Winning Excellence — Industry Recognition
2024 Merck Biotech Grant — Grand Prize
2024 21st National Innovation Award — Enterprise Innovation Award
2025 IMAPAC Taiwan Biopharma Excellence Awards
2025 Taiwan Bio Industry Organization — Outstanding Startup Award

HanchorBio, founded in late 2020 by Dr. Shih-Kao Liu, co-founder of the Hong Kong-listed company Henlius, was officially listed on the Taipei Exchange (TPEx: 7827.TWO) in 2025. The company specializes in developing innovative fusion protein biologics for cancer and autoimmune diseases, striving to become a global leader in next-generation oncology therapies.

Leveraging its proprietary FBDB™ technology platform, HanchorBio flexibly integrates diverse therapeutic targets to establish a new paradigm of precision cancer treatment. Through distinctive drug design and clinical development strategies, the company advances cancer therapy toward a safer and more effective future.

Backed by industry-leading fusion protein design capabilities and an accelerated drug development process, HanchorBio continues to expand its R&D pipeline across multiple oncology indications, unlocking the full potential of biopharmaceutical innovation.

As of 2025, HanchorBio has advanced more than eight R&D programs via the FBDB™ platform, covering areas such as immune checkpoints, tumor microenvironment modulation, and tumor-specific antigens. Globally, the company has filed over 100 patent applications, demonstrating robust innovation and intellectual property strength. HanchorBio operates across Taipei, Shanghai, and San Francisco, with its primary R&D center located in Taipei.
aiwan-developed tri-functional fusion protein innovative biologic
# 1
R&D programs
8 +
Clinical-stage development programs
2
Team comprised primarily of master’s and Ph.D. professionals in biomedical sciences
80 %

Mission Statement

Through the development of multifunctional and structurally innovative biologics, HanchorBio aims to overcome the bottlenecks of tumor immunotherapy and benefit cancer patients worldwide.

Company Vision

By pioneering breakthroughs in multifunctional molecular design, we strive to open new frontiers in biologics innovation and become a globally respected, trailblazing biotechnology company.

Our Values

Courage to Innovate
Operational Efficiency
Pursuit of Excellence
Integrity and Honesty
Accountability
Teamwork

Leadership Team

An international executive team with extensive experience in new drug research and development as well as management
Founder & Chairman (CEO) Dr. Scott Liu
Scott, PhD
With over 30 years of experience in biopharmaceutical development, manufacturing, and global pharmaceutical management, he is a highly respected entrepreneur with an outstanding track record in biologics innovation and corporate growth. He has led the development of more than 30 biologics, including biosimilars, novel biologics, innovative vaccines, and combination immunotherapies.
Chief Business Officer (CBO) Yuehua Cong
Yuehua, PhD
Dr. Yuehua Cong has extensive experience in business development and investment in the life sciences industry, gained from roles at PolyTherics, F-star Biotech, and Simcere Pharmaceutical. She is highly skilled in international partnerships and has successfully executed licensing and collaboration deals totaling approximately USD 400 million to 1.2 billion. With hands-on experience in company formation and a multidisciplinary scientific background, she combines visionary leadership with strong teamwork. Dr. Cong holds a Ph.D. in Organic Chemistry from the University of Konstanz, Germany.
Group President and Chief Medical Officer, Alvin Luk
Alvin LUK PhD, MBA, CCRA
Over 30 years of global clinical development experience; formerly served at the FDA, where they led the successful approval of the FDA’s first gene therapy, LUXTURNA®; contributed to the approval of 22 marketed drugs and submitted over 250 global regulatory filings.
Chief Financial Officer (CFO) Mu-Tseng Tseng
Alan, EMBA
Mr. Mu-Tseng Tseng has over 25 years of experience in corporate financial planning and IPO management, covering IPO/SPO fundraising, bank financing, capital structure optimization, budgeting, and internal control enhancement, with a professional background in auditing at Deloitte. He has also supported executive strategic planning and served as a corporate spokesperson. Mr. Tseng holds an Executive MBA in Management from National Taiwan University of Science and Technology.
Chief Scientific Officer (CSO) & General Manager of R&D, Wenwu Zhai
Wenwu Zhai, MD, PhD
Dr. Wenwu Zhai has over 20 years of experience in the development of therapeutic antibodies and protein drugs, with extensive expertise spanning from preclinical research to IND submission and Phase I clinical trials. He holds 107 published or granted patents and has led scientific teams ranging from 5 to 150 members. His research focuses on oncology/immuno-oncology, autoimmune diseases, neurodegenerative disorders, metabolic diseases, and infectious diseases. Dr. Zhai completed his Ph.D. at the University of Manchester, UK, and conducted postdoctoral research at the University of Cambridge.
/
Founder & Chairman (CEO) Dr. Scott Liu
Scott, PhD

  • Over 30 years of experience in biopharmaceutical development, manufacturing, and global pharmaceutical management

  • Co-founder and former Chief Executive Officer of Shanghai Henlius Biotech (a subsidiary of Fosun Pharma Group)

  • Highly respected entrepreneur with an outstanding track record in biologics innovation and corporate growth

  • Led the development of over 30 biologics, including biosimilars, novel biologics, innovative vaccines, and combination immunotherapies

  • Oversaw the full R&D-to-commercialization process for 8 approved biologic products

  • Ph.D. in Biological Sciences, Purdue University, USA

  • Postdoctoral Research Fellow in Biological Sciences, Stanford University, USA

Chief Business Officer (CBO) Yuehua Cong
Yuehua, PhD

  • Extensive experience in business development and investment in the life sciences industry, with prior roles at PolyTherics, F-star Biotech, and Simcere Pharmaceutical

  • Highly proficient in international partnerships, with an exceptional track record in licensing and collaboration deals totaling approximately USD 400 million to 1.2 billion

  • Experienced in company formation, with a strong multidisciplinary scientific background, visionary leadership, and a collaborative spirit

  • Ph.D. in Organic Chemistry, University of Konstanz, Germany

Group President and Chief Medical Officer, Alvin Luk
Alvin LUK PhD, MBA, CCRA

  • Over 30 years of global clinical development experience

  • Former FDA official; led the successful approval of LUXTURNA®, the FDA’s first gene therapy

  • Contributed to the approval of 22 marketed drugs and submitted 250+ global regulatory filings

  • Master of Management, Harvard Business School

  • Ph.D. in Neuroscience, School of Medicine, University of California, San Francisco (UCSF)

  • M.S. in Cell, Developmental & Physiological Biology and B.S. in Biochemistry, University of California, Berkeley

  • Formerly held leadership roles at Spark Therapeutics, Biogen, Bayer, Henlius, Neurophth Biotech, and Pfizer Gene Therapy, among other leading global biotechnology and pharmaceutical companies

Chief Financial Officer (CFO) Mu-Tseng Tseng
Alan, EMBA
  • Over 25 years of experience in corporate financial planning and IPO-related operations
  • Expertise in IPO listing, SPO fundraising, and bank financing
  • Proven track record in optimizing capital structure, annual budgeting, and performance tracking
  • Experienced in internal control process enhancement, with an auditing background at Deloitte
  • Strong operational support and involvement in executive strategic planning
  • Corporate spokesperson representing the company to banks, securities firms, auditors, investors, and media
  • Executive MBA in Management, National Taiwan University of Science and Technology
Chief Scientific Officer (CSO) & General Manager of R&D, Wenwu Zhai
Wenwu Zhai, MD, PhD
  • Over 20 years of experience in therapeutic antibody and protein drug development, covering the full spectrum from preclinical research to IND and Phase I clinical trials; holder of 107 published or granted antibody patents
  •  Led scientific teams ranging from 5 to 150 members, with research focused on oncology/immuno-oncology, autoimmunity and inflammation, neurodegenerative diseases, metabolic disorders, and infectious diseases
  • Postdoctoral Research Fellow, University of Cambridge, UK
  •  Ph.D., University of Manchester, UK

Management Team

A management team with extensive experience in new drug research and development.
/
Senior Director, Research & Development (R&D), Jin-Tang Wang
Jonathan Ph.D.
Vice President, Research & Development (R&D) Chi-Ling Tseng
Chi-Ling, Ph.D.
Senior Director, Process Development & CMC, Meng-Wei Kuo
Vivian Ph.D.
Senior Director, Research & Development (R&D), Jin-Tang Wang
Jonathan Ph.D.

  • 15 years of academic and biopharmaceutical drug development experience

  • Led 5 preclinical research programs and advanced 1 project to the IND stage at Shanghai Henlius Biotech

  • Led more than 6 preclinical research programs and advanced over 2 projects to the IND stage at HanchorBio

  • Ph.D. in Life Science, National Taiwan University

Vice President, Research & Development (R&D) Chi-Ling Tseng
Chi-Ling, Ph.D.

  • 20 years of experience in innovative biopharmaceutical R&D (monoclonal antibodies, bispecific antibodies, and vaccines)

  • Former Head of R&D at Shanghai Henlius Biotech (Taiwan)

  • Participated in the development of over 20 mono- and bispecific antibody programs, 9 IND-enabling studies, and more than 15 patent applications

  • Ph.D. in Biochemistry and Molecular Biology, National Yang Ming University, Taiwan

Senior Director, Process Development & CMC, Meng-Wei Kuo
Vivian Ph.D.
  • Over 14 years of academic and industry experience specializing in CMC development for biopharmaceutical drug substances and formulations
  • Led more than 20 CMC projects from laboratory stage to clinical and BLA submission phases
  • Former Chief Scientist and Director of Process Development at Shanghai Junshi Biosciences (China), TaiMed Biologics, and Eden Biologics
  • Ph.D., National Tsing Hua University, Taiwan

Awards

Repeatedly Honored and Highly Recognized for Excellence
/
2025 IMAPAC Taiwan Biopharma Excellence Awards
2025 Taiwan BIO Awards – Startup of the Year
Awarded the 21st National Innovation Award – Corporate Innovation Category, 2024
HCB303: Entered the IND-enabling stage.
Since its establishment in 2020, HanchorBio has been dedicated to developing innovative biologics for the treatment of cancer and autoimmune diseases.
Our proprietary FBDB™ (Functional Bispecific Discovery and Building) technology platform has opened new possibilities in tumor therapy, paving the way for next-generation immuno-oncology treatments.
Conference Call
HCB301: IND approval obtained in China; Phase I multi-center clinical trial initiated.
Listed on the Emerging Stock Board (Taiwan OTC Market)
HCB101: Entered Phase IIa clinical trial
HCB101: Last Patient In (LPI)
HCB301: IND approval obtained in the U.S.
HCB101: IND approval obtained in China; Phase I clinical trial initiated at the third study site.
HCB101: IND approvals obtained in the U.S. and Taiwan; Phase I multi-center clinical trial initiated
HCB101: Demonstrated preliminary results in cell-based and animal studies.
Five R&D programs initiated, including the development of Taiwan’s first tri-functional anti-cancer biologic.
Establishment of HanchorBio Group
2020
Establishment of HanchorBio Group
2025
HCB303: Entered the IND-enabling stage.
2021
Five R&D programs initiated, including the development of Taiwan’s first tri-functional anti-cancer biologic.
2022
HCB101: Demonstrated preliminary results in cell-based and animal studies.
2023
HCB101: IND approvals obtained in the U.S. and Taiwan; Phase I multi-center clinical trial initiated
2024
HCB101: IND approval obtained in China; Phase I clinical trial initiated at the third study site.
2024
HCB301: IND approval obtained in the U.S.
2025
HCB101: Last Patient In (LPI)
2025
HCB101: Entered Phase IIa clinical trial
2025
Listed on the Emerging Stock Board (Taiwan OTC Market)
2025
HCB301: IND approval obtained in China; Phase I multi-center clinical trial initiated.
2025
Conference Call